Chek the Channels
Companies by Sector
Meet 125 Mgmt Teams
ChannelCASTS
Company
Title
Townsquare Media Inc. Class A
2019 Radio Show: Bill Wilson Opening
Enochian Biosciences Inc.
Introduction
Aurania Resources Ltd.
NobleConXV
QuoteMedia Inc.
NobleCon XV
Tribune Publishing Company
NobleConXV
Townsquare Media Inc. Class A
NobleConXV
The KEYW Holding Corporation
NobleConXV
Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals at NobleConXV
Salem Media Group Inc.
NobleConXV
Information Services Group Inc.
NobleConXV
Salem Media Group Inc.
Salem Media Group at NobleCon
IEC Electronics Corp.
IEC Electronics at NobleConXV
Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Limited at NobleConXV
Torchlight Energy Resources Inc.
Torchlight Energy Resources, Inc. at NobleConXV
Endeavour Silver Corporation (Canada)
Endeavour Silver Corporation at NobleConXV
Eagle Bulk Shipping Inc.
Eagle Bulk Shipping at NobleConXV
Sierra Metals Inc.
Sierra Metals Inc. at NobleConXV
Altimmune Inc.
Altimmune Inc at NobleConXV
Arcadia Biosciences Inc.
Arcadia Biosciences Inc at NobleConXV
Brainstorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics at NobleConXV
Genie Energy Ltd. Class B Stock
NobleConXV
Dyadic International Inc.
Dyadic International at NobleConXV
Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corporation at NobleConXV
One Stop Systems Inc.
NobleConXV
Great Panther Mining Limited (Canada)
Great Panther Silver at NobleConXV
electroCore Inc.
NobleConXV
Pyxis Tankers Inc.
Pyxis Tankers Inc. at NobleConXV
Comtech Telecommunications Corp.
Comtech Telecommunications Corp. at NobleConXV
Pangaea Logistics Solutions Ltd.
Pangaea Logistics Solutions Ltd. at NobleConXV
Seanergy Maritime Holdings Corp
Seanergy Maritime Holdings at NobleConXV
TrovaGene Inc.
TrovaGene Inc at NobleConXV
Industry Research Report Release
Share  
 

Wednesday, August 7, 2019

Biotechnology YTD

Biotechnology Industry Overview

Ahu Demir, Ph.D., Biotechnology Research Analyst & Cosme Ordonez, M.D., Ph.D, Senior Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

  • Index Performances: NYSE Arca Biotechnology (BTK, +5.8%) and NASDAQ Biotechnology (NBI, +5.6%) have underperformed benchmark indices S&P 500 (SP50, +13.5%) and Russell 3000 (RUA, +13.5%) YTD (as of August 5, 2019) (Exhibit 1). In H1 2019, the stock markets recovered following a steep plunge in Q4 2018. The start of the third quarter has shown a modest slowdown in the markets, including the biotechnology sector.
  • Equity Financing: Overall, biotech financing remained flat in H1 2019 compared to H1 2018. The total monies raised was $4.2 billion. The capital raised by initial public offerings (IPO) in Q1 2019 represented the highest median number since 2011 ($166mm) (Exhibit 5).
  • FDA Approvals: Thus far, U.S. Food and Drug Administration (FDA) has approved 19 drugs in YTD-2019 compared to a record year in 2018 with 59 approvals (Exhibit 12 and 13). 
  • Sector Overview. The biotechnology sector underperformed the broader capital markets in Q2 2019. The lack of major catalysts in the quarter, combined with drug pricing pressure, have had a negative impact on the sector. Going forward, we expect the sector to rebound in the second part of the year, driven by an increase in M&A activity and positive news from ongoing late-stage clinical trials.

Overview

M&A DEALS AS A KEY CATALYST FOR BIOTECHNOLOGY STOCKS

As big pharmaceutical companies continue to face patent expirations, we expect a relatively high level of M&A activity to persist in the biotechnology sector. As such, we expect big pharma to keep hunting for novel promising technologies heating up the M&A barometer in biotech. In our opinion, the primary beneficiary of an M&A wave will be small biotechnology companies, which are built upon innovation. For many years now, small biotechs have attracted the buying power of larger pharmaceutical companies. Going forward, we expect this trend to endure. Although outright acquisitions are one of the main catalysts for the biotech sector, big pharma has also consistently struck high value partnerships with small biotech companies, both private and publicly held. Through strategic collaborations, big pharma gets access to innovative technologies developed by small biotechnology companies, whereas the smaller firms get to see their coffers grow rich by receiving upfront and milestone payments from their larger competitors. All of this is to the delight of biotech investors. 

Bellwether Pfizer is Leading the Charge

In June, big pharma company Pfizer Inc. (PFE) announced its intention to acquire Array BioPharma Inc. (ARRY) for $11.4 billion in cash. Array’s share price skyrocketed 57% on the news. The deal was completed on July 31, 2019. This is the largest acquisition made by Pfizer since the giant pharma company bought Medivation for $14 billion three years ago. The acquisition of Array triggered a rally in the shares of cancer companies as investors hope for similar deals taking place in 2019. By acquiring Array BioPharma, Pfizer added BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) to its product pipeline. These medicines are approved by FDA for the treatment of metastatic melanoma, a type of skin cancer, and are currently being evaluated in Phase III clinical trials for the treatment of metastatic colorectal cancer. Both drugs, encorafenib and binimetinib, target mutations in an oncogene known as BRAF, which is involved in signal transduction pathways controlling cell proliferation. In various human cancers, BRAF gene is mutated leading to tumor growth and progression.

Big Pharma Companies Showing Strong Appetite for Private Biotechnology Companies 

In Q2 2019, Merck & Co.’s management explained to investors that it is looking for small and midsize M&A transactions, especially those expanding its cancer product portfolio to complement Keytruda, the company’s top selling blockbuster drug. Last year, global sales of Keytruda reached $7 billion. In the quarter, Merck bought two privately held companies, Tilos Therapeutics Inc. and Peloton Therapeutics Inc., for $773 million and $1.1 billion, respectively, plus milestone payments. Through the acquisition of Tilos, Merck has now access to candidate medicines targeting the “latent TGF Beta complex” for the treatment of cancer, fibrosis and autoimmune diseases. The transforming growth factor beta (TGF Beta) binds to “latency-associated peptide” (LAP), which is a therapeutic target for various disease indications. TGF Beta plays an instrumental role in inflammation and immune responses. The role of the latency-associated peptide is to regulate TGF Beta functions. Tilos has developed a portfolio of anti-LAP antibodies designed to maximize the therapeutic effects of TGF Beta drugs.

By acquiring Peloton, Merck will add to its oncology drug pipeline a series of novel small molecule therapeutics targeting “HIF-2 alpha” (hypoxia-inducible factor-2 alpha). Peloton’s lead candidate medicine, PT2977, is in late-stage clinical development for the treatment of renal cell carcinoma (RCC). RCC is the most common type of kidney cancer in adults. Under the terms of the agreement, Merck will pay $1.05 billion in cash. Also, Peloton will be eligible to receive $1.15 billion in additional payments upon achieving certain regulatory and commercial milestones. The deal is expected to close in Q3 2019. 

In July, big pharma companies AbbVie (ABBV) and Boehringer Ingelheim announced the acquisitions of Mavupharma and AMAL Therapeutics SA, two privately held biotechnology companies in the cancer area. Mavupharma is focused on the development of novel candidate medicines targeting the STING (“STimulator of INterferon Genes”) pathway for the treatment of cancer. Mavupharma’s lead drug is MAVU-104, a small molecule drug designed to stimulate the STING pathway to induce an anti-cancer immune response. AMAL Therapeutics SA is developing cancer vaccines. AMAL’s lead product is ATP128, a vaccine for the treatment of advanced colorectal cancer, which is expected to enter human clinical trials this quarter. AbbVie and Boehringer did not disclose the financial terms of the deals. 

Gilead Hoping to Stay Competitive by Signing Multiple Strategic Collaborations

Large biotechnology company Gilead (GILD) is building a robust immune-oncology pipeline. In Q2 2019, the bellwether signed two global strategic collaborations with Nurix Therapeutics (private) and Carna Biosciences Inc (CBIXF). Under the terms of the deal with Nurix, Gilead is paying $45 million upfront and up to $2.3 billion in potential milestone payments to add candidate drugs in the “protein degradation area” (targeting the proteasome). Proteasomes are protein complexes located both in the cellular nucleus and cytoplasm, with its main function being getting rid of undesired proteins. The proteasome functions as a “garbage disposal” in the cell. Through the collaboration with Nurix, Gilead will have the option to develop protein degradation drugs for the treatment of cancer and four other diseases.

Under the terms of the deal with Japanese company Carna, Gilead will pay an upfront payment of $20 million. Carna will be eligible to receive up to $450 million in potential milestone payments plus a royalty on future net sales. Gilead will have access to a proprietary platform to develop novel kinase inhibitor drugs targeting cellular lipid signaling. These candidate drugs will be developed for the treatment of cancer.

Outside of cancer, Gilead is also strengthening its leadership position in HIV area. Last month, Gilead signed an agreement with DURECT (DRRX) to get exclusive access to DURECT’s technology (sustained release of long-acting injectable medicines) for the treatment of HIV and HBV (hepatitis B virus) infections. This drug delivery technology enables high drug-loading, controlled onset and sustained release of the medicine for days to months after injection. Gilead paid an upfront payment of $25 million, plus payments of $145 mm upon achieving certain regulatory and sales milestones. In addition, Gilead plans to pay $150 million for any additional products coming out of the collaboration. Since the deal was announced, DURECT’s share price has gained 87%.

Also last month, Gilead signed a 10-year global R&D transformative collaboration with Galapagos NV (GLPG). Gilead will have access to six candidate medicines in human clinical trials, more than 20 preclinical programs and a promising drug discovery platform in exchange for a $3.95 billion upfront payment and $1.1 billion equity investment at a 20% premium to Galapagos’ 30-day, volume-weighted average price. In addition, Galapagos is entitled to milestone payments and royalties. The transaction is expected to close in Q3 2019.

What is in Store for H2 2019

In our view, recent deals are manifestations of a trend, which we expect to persist as a primary catalyst for biotechnology stocks. In Q1 2019, the industry saw M&A deals to surpass the $92 billion mark. Although the deal count is relatively lower in recent months, the relative size of these deals has significantly increased in recent years, with more transactions involving private rather than publicly traded biotech companies (Exhibit 7). Prominent deals in Q1 2019 were the acquisitions of Celgene by Bristol-Myers Squibb for $74 billion, Eli Lilly acquiring Loxo for $8 billion, and Roche acquiring Spark Therapeutics for $4.8 billion. Pharma bellwether Pfizer highlighted Q2 2019 with its $11.4 billion acquisition of Array BioPharma. Investors continue to monitor the industry, eagerly anticipating new M&A developments in the second half of 2019. High value M&A deals and strategic partnerships will be welcome news for biotech investors.


Market Dynamics

Thus far this year, the biotechnology sector has underperformed compared to 2018. With a lower number of FDA drug approvals, amid recent general weakness in the capital markets, biotech investors have stayed on the sidelines. The lack of major catalysts in Q2 2019, combined with drug pricing pressure, have had a negative impact on the sector. In March, Biogen disappointed investors with negative news from its Phase III trials evaluating aducanumab for the treatment of Alzheimer’s disease. The news diminished hopes of finding a potential blockbuster drug for the treatment of Alzheimer’s any time soon. However, we believe that the fundamentals of the biotechnology sector remain healthy, with a number of promising drugs in the pipeline targeting other large commercial opportunities. We expect the sector to rebound in the second part of the year, driven by an increase in M&A activity and positive data from ongoing clinical trials. 

Exhibit 1: Biotechnology Relative Price Performance, YTD 2019 (as of August 5,2019)

Source:  Noble Life Science Research, Capital IQ

S&P 500 (SP50, +13.5%) and Russell 3000 (RUA, +13.5%) benchmark indices have outperformed the NYSE Arca Biotechnology (BTK, +5.8%) and NASDAQ Biotechnology (NBI, +5.6%) indices in YTD- 2019 (as of 8/5/2019). Notable stock price outperformance in the BTK index (in alphabetical order) include Acadia (ACAD, +87.8%), Exact Sciences (EXAS, + 115.1%), Incyte (INCY, +28.4%), Ionis Pharma (IONS, + 42.1%) and Iqvia (IQV, +23.3%).

 

Exhibit 2: Top/Bottom 5 Small Cap Stock Performance, 1 year (as of August 5/2019)

 

Source:  Noble Life Science Research, Capital IQ

Top stock performers of NBI index include Amarin Corporation (AMRN, +529.2%), Ra Pharmaceuticals (RARX, +246.9%), Adverum Biotechnologies (ADVM, + 146.8%), NovoCure Limited (NVCR, +136.0%), Veracyte Inc. (VCYT, +113.9%); bottom performers include Aclaris Therapeutics (ACRS, -94.0%), Zafgen Inc. ( ZFGN, -90.4%), Acorda Therapeutics (ACOR, -88.9%), Lexicon Pharmaceuticals (LXRX,-87.8%) and Unum Therapeutics (UMRX, -87.5%).

 

Exhibit 3: Biotechnology Short Interest % of Float, as of 8/5/19

 

Source: Noble Life Science Research, Capital IQ

Stocks with highest short interest are Opko Health Inc. (OPK), Therapeutics MD (TXMD) and Geron Corporation (GERN).

 

Market Dynamics—Financing

 Exhibit 4: Biotech Financing YTD-2019 (between $50-$200mm)

Source:  Noble Life Science Research, Capital IQ

The largest transactions include Alector Inc. (ALEC, $176mm), Zai Lab Ltd (ZLAB, $200 mm) and Intercept Pharmaceuticals (ICTP, $200 mm).


Exhibit 5: Biotech Financings—IPO and Follow-on Capital Raised by Quarter (Median)

Source:  Noble Life Science Research, Capital IQ

Biotech financings in YTD-2019 has already exceeded the full year of 2018 numbers ($535mm vs. $527mm, respectively). This was a result of large transactions, initial public offering (IPO) in Q1 2019, including Alector Inc. (ALEC, $175mm), Turning Point Pharmaceuticals Inc. (TPTX, $166mm) and Precision Biosciences (DTIL, $126mm).


Exhibit 6: Biotech Licensing Deals

Source:  Noble Life Science Research, Bloomberg

The licensing deal transactions in H1 2019 showed a modest decrease of 5% compared to H1 2018.


Exhibit 7: Biotech M&A Deals

Source:  Noble Life Science Research, Bloomberg

The size of private M&A deals showed an uptick (+19%) in 1H 2019 compared to 1H 2018.


Lock-Up Expirations

Exhibit 8: IPO and Follow-On Lock-Up Expiration Data for 2019 

Source:  Noble Life Science Research, Bloomberg


Selected Industry Conferences

Exhibit 9: Medical, Scientific and Industry Conferences for 2019

Source:  Noble Life Science Research, Biomed Tracker


FDA Approvals

Exhibit 10: Selected Pending Approvals of New Molecule Entities (NMEs) and Biologics

Source: Biomed Tracker, FDA

Exhibit 11: Upcoming Advisory Committee Meeting Dates

Source: Noble Life Science Research, FDA


Exhibit 12: Selected Recently Approved Drugs and Biologics, YTD

Source: Noble Life Science Research, Biomed Tracker, FDA

In total, 19 medicines were approved in YTD-2019. The table does not include the approval of Zolgensma, which instead of a drug is a gene therapy. Zolgensma was developed by AveXis Inc., which was acquired by Novartis in 2018. Zolgensma is the first gene therapy approved for the treatment of spinal muscular atrophy (SMA), a leading cause of death in children. SMA is a rare genetic disease caused by a mutation in the “survival motor neuron 1” (SMN1) gene. Children with SMA cannot perform essential functions of life, cannot hold their heads up, nor can swallow and breath properly.


Drug Landscape

Exhibit 13: New FDA Drug Approvals

Source: Noble Life Science Research, Bloomberg

19 drug approvals in 2019 (YTD) demonstrated a low productive year following all-time record of 59 approvals in 2018.

 

Exhibit 14: Number of Drugs in the Pipeline

Source: Noble Life Science Research, Global Data Intelligence

Oncology continues to be the dominant development category, which we think has also been fueled of late by the 1000+ immuno-oncology clinical drug trials.


Appendix

Exhibit 15: Cash Analysis, sorted by E/P

 

Note: Market cap as of 8/5/2019, Cash value for 2Q19

Source: Noble Life Science Research, Capital IQ


Exhibit 16: Catalyst Calendar (Market Cap $10-250mm)

  


Source: Noble Life Science Research, Biomed Tracker 

GENERAL DISCLAIMERS: All statements or opinions contained herein that include the words "we", "us", or "our" are solely the responsibility of Noble Capital Markets, Inc. ("Noble") and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES: This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. ("Noble"). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst's judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures: The following disclosures relate to relationships between Noble and the company (the "Company") covered by the Noble Research Division and referred to in this research report.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months


ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Equity Research Analyst focusing on the Life Sciences sector. 5 years of industry experience. PhD in Chemistry from University of Florida.Post-Doctoral training at Columbia University and New York University. Her scientific training focused on antiviral therapy, oncology and immuno-oncology. 
FINRA licenses 7, 63, 86, 87.

Senior Equity Analyst focusing on Life Sciences. More than 16 years of experience in his field. Former President and co-founder of Ciclofilin Pharmaceuticals. Held various roles in Buy-side and Sell-Side specializing in drug development, medical device, specialty pharma and healthcare services areas. Medical Doctor with a Ph.D. in Experimental Medicine and Biochemistry from McGill University in Montreal, Canada. Completed post-doctoral training at the Karolinska Institute/Hospital in Stockholm, Sweden. 
Holds FINRA licenses 7, 79, 86, 87.

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc..


RESEARCH ANALYST CERTIFICATION

Independence Of View

All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation

No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest

Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.


NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from "Buy" to "Outperform", from "Hold" to "Market Perform" and from "Sell" to "Underperform." The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.


Noble Capital Markets, Inc.

225 NE Mizner Blvd. Suite 150

Boca Raton, FL 33432

561-994-1191


Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer. Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer. Member - SIPC (Securities Investor Protection Corporation)

Report ID: 11022




NEWS Channel
  Research - Pangaea Logistics Solutions (PANL) - Unique Business Model Delivers Solid Results, 11/11/2019
  Research - Information Services Group Inc. (III) - Additional 3Q19 Comments; Updated Projections, 11/11/2019
  Research - E.W. Scripps Company (SSP) - What Is At The Core Of Q3 Results?, 11/11/2019
  Research - Trovagene (TROV) - Q3 2019 Results: Trovagene Continues Progressing, 11/11/2019
  Research - Eagle Bulk Shipping (EGLE) - Stock Price Weakness Spells Opportunity, 11/08/2019
  Research - Entravision Communications Corporation (EVC) - What It Can Do To Change The Narrative?, 11/08/2019
  Research - Gray Television (GTN) - Does Q3 Political Indicate a Windfall for 2020, 11/08/2019
  Research - One Stop Systems Inc. (OSS) - Strong 3Q19 Sets Stage for Excellent Full Year 2019, 11/08/2019
  Research - Tribune Publishing Company (TPCO) - Why This Quarter Reflects The Quality Of Its Cash Flow, 11/08/2019
  Research - Genco Shipping (GNK) - Improving Financials and Asset Sales Trigger Special and Regular Dividends, 11/07/2019
  Research - Information Services Group (III) - Mixed Third Quarter Results, But Record Adjusted EBITDA and Strong Cash Generation, 11/07/2019
  Research - Kelly Services Inc. (KELYA) - What Was Behind the Disappointing 3Q19 Results?, 11/07/2019
  Research - Seanergy (SHIP) - 3Q2019 Shortfall Masks Improving Operating Results, 11/07/2019
  Today's Feature, 11/07/2019
  Research -Coeur Mining (CDE): Q3 Results Better Than Expected; Increasing Estimates, 11/06/2019
  Research - Endeavour Silver (EXK): Third Quarter In Line With Our Expectations; Lowering 2020 Estimates, 11/06/2019
  Research - Great Lakes Dredge & Dock (GLDD): Backlog rebounded and set up for strong finish to year, 11/06/2019
  Research - Kratos Defense & Security (KTOS): Another Solid Quarter But Will Continuing Resolution Hit The Pause Button?, 11/06/2019
  Research - Townsquare Media (TSQ): Scores Another Good Quarter , 11/06/2019
  Research - Vectrus (VEC): Can Outperformance Continue?, 11/06/2019
  Are Strong Earnings a Sign that Economic Concerns are Unwarranted? , 11/05/2019
  Taking Stock of Index Funds, 11/04/2019
  Research - Energy Fuels (UUUU) - No Big Surprises , 11/04/2019
  Research- Great Panther Mining (GPL) - Q3 Falls Short on EPS but Exceeds on EBITDA, 11/01/2019
  Research - Orion Group Holdings (ORN) - On the Right Track. Moving Up Estimates., 11/01/2019
  Research - 1-800-Flowers.com (FLWS) - A Surprisingly Good Harvest, 11/01/2019
  Research - ACCO Brands (ACCO) - Post 3Q19 Conference Call Notes, 10/31/2019
  Research - ORION Group Holdings - Transition Continues with Another Solid Quarter., 10/31/2019
  Research - ACCO Brands (ACCO) - Record 3Q19 Cash Flow; But Top and Bottom Lines Weaker than Expected, 10/30/2019
  Research - Comtech (CMTL) - A Troposcatter Win for Comtech?, 10/30/2019
  Waning Stock Buybacks: Should Investors be Worried? , 10/29/2019
  Sins of Omission , 10/29/2019
  Research - Genco Shipping (GNK) - Adjusting Estimates for Updated Scrubber Program Progress, 10/28/2019
  Research - Onconova Therapeutics (ONTX) - Completion of Enrollment is Pushed Back but Data Readout is on Track, 10/25/2019
  Was the US Right in Removing Troops from Syria?, 10/25/2019
  Industry Report - Noble Capital Markets Biotechnology Industry Overview, 10/25/2019
  Research - ProMIS Neurosciences (PMN:CA) - Is ProMIS’ Alzheimer’s Antibody Better Than Biogen’s?, 10/24/2019
  Research - Scorpio Bulkers (SALT) - Making A Good Move With Special Dividend, 10/24/2019
  Research - Aurania Resources (ARU:CA) - Full Speed Ahead, 10/23/2019
  Research - Genco Shipping (GNK) - 2H2019 Recovery Intact Despite Recent Weakness, 10/23/2019
  Looking for Money Growing on Trees? Try Timber., 10/22/2019
  Is Fracking Safe?, 10/22/2019
  Brant Pinvidic, Host of IPO Podcast Series, on the Channelchek College Research Report Challenge, 10/21/2019
  Can Biosimilars Finally Be Successful in the US?, 10/18/2019
  Research - Seanergy (SHIP) - Positive Impact from Dry Bulk Market Firmness, 10/17/2019
  Research - Great Panther Mining Limited (GPL) - GPL Cuts 2019 Production Guidance; Lowering Estimates and Price Target, 10/17/2019
  Research - Sierra Metals (SMTS) - Third Quarter Production Above Expectations; Raising Estimates, 10/17/2019
  Research - Avino Silver & Gold (ASM) - Avino Reports Third Quarter 2019 Production; Dropping Research Coverage, 10/17/2019
  Research Initiation - Akazoo (SONG) - Getting The Company For A Song, 10/16/2019
  Research - Scorpio Bulkers (SALT) - Dry Bulk Market Firmer, But Fine-Tuning 2H2019 Estimates, 10/16/2019
  Research - DLH Holdings Corp. (DLHC) - Announces Preliminary Results for FY19, 10/16/2019
  Research - Coeur Mining (CDE) - Laying the Groundwork for Improved Performance in 2020, 10/14/2019
  Show Me the Money: Should College Athletes Play for Pay?, 10/14/2019
  Going to the Movies? A Theater or Stream?, 10/11/2019
  Are Planned Power Outages Worth the Cost? , 10/11/2019
  Research - Endeavour Silver (EXK) - Still In Turnaround Mode; Visible Path for Improvement, 10/10/2019
  Industry Report - Media - Is The Sell-Off Over?, 10/10/2019
  Developing a Research Driven Approach: an Investment Bank’s Perspective Webinar, 10/10/2019
  Investing in Microcap Biotech Stocks, Risks and Rewards, 10/09/2019
  How Long Will U.S. Petrochemical Producers Maintain Their Global Advantage?, 10/09/2019
  NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference, 10/09/2019
  Ducommun Incorporated Acquires Nobles Worldwide, 10/09/2019
  Industry Report - Energy - Summer's End Brings No Relief For Energy Stocks, 10/08/2019
  Who Is to Blame for the Weak Manufacturing Number and the Market Crash? , 10/08/2019
  Industry Report - Metals & Mining Third Quarter Review and Outlook, 10/07/2019
  Research - Eagle Bulk Shipping (EGLE) - Scrubber Program Change Impacts Estimates, But Outlook Remains Solid, 10/07/2019
  Research - QuoteMedia, Inc. (QMCI) - Could A Bear Market Help This Company?, 10/04/2019
  What’s Going on with the IPO Market?, 10/04/2019
  IPO Podcast - Vanessa Van Edwards, 10/04/2019
  Research - Great Panther Mining Limited (GPL) - Raising Estimates Based on Improving Outlook, 10/03/2019
  Research - Orion Group Holdings (ORN) - Two Marine Awards Help 2020 Outlook, 10/03/2019
  Research - Great Lakes Dredge & Dock (GLDD) - Total 3Q2019 Awards of $319 million Above Expectations., 10/03/2019
  Research - Great Lakes Dredge & Dock (GLDD) - Two New Jobs - 3Q2019 Awards Likely Above $265 million, 10/02/2019
  Research - electroCore (ECOR) - What Do Recent Developments Mean For electroCore?, 10/02/2019
  Research - Kratos Defense & Security - Risk-Reward Turns Favorable. Upgrading Rating, 10/02/2019
  Research - Euroseas (ESEA) - One Good Contract But Rest of the Fleet Not Following...Yet., 10/01/2019
  Research - Sierra Metals (SMTS) - Looking Ahead to 2020, 10/01/2019
  Research - Trovagene (TROV) - Number of Patients with a Complete Response Increases in AML Study, 10/01/2019
  Positive Data from Trovagene Phase 1b_2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference, 09/30/2019
  IPO Podcast Series: Vanessa Van Edwards, 09/30/2019
  Research - Great Lakes Dredge & Dock (GLDD) - Backlog Rebound, 09/27/2019
  Research - Kelly Services (KELYA) - What's Next?, 09/27/2019
  Research - TherapeuticsMD (TXMD) - On Track for Annovera Soft Launch, 09/27/2019
  NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Building Encouraging New Breast Cancer Treatment Options, 09/27/2019
  Research - Energy Fuels (UUUU) - Relief on the Horizon?, 09/26/2019
  Research - EuroDry (EDRY) - Moving Estimates Higher, 09/26/2019
  Research - Comtech (CMTL) - Raising PT, 09/25/2019
  Smallcap Rally: Russel 2000 Trumps S&P 500 in September , 09/25/2019
  Will New 2020 Climate Change Policies Affect the Market? , 09/25/2019
  Noble Capital Markets Launches Small and Microcap Equity Research Contest, 09/25/2019
  Research - Scorpio Bulkers (SALT) - Will Dry Bulk Market Remain Firm?, 09/24/2019
  Cut to the Chase: The Reality of Rate Cuts, 09/24/2019
  Boeing 737 MAX: What’s Taking So Long?, 09/24/2019
  Research - Endeavor Silver (EXK) - Rating Upgrade, 09/23/2019
  Research - Aurania Resources (ARU.V) - Closed Private Placement, 09/23/2019
  Research - Kratos (KTOS) - Momentum in Unmanned Systems, 09/23/2019
  Silver Still has a Place on the Winners’ Podium, 09/23/2019
  Noble Capital Markets Supports Bahamas Relief Fund Through its NobleCon Investor Conference, 09/23/2019
  Can Smallcap Funds Help Cap Index Overlap in Your Portfolio? , 09/20/2019
  Is the US Accelerating toward Becoming the World’s Energy Capital? , 09/20/2019
  Research - Orion (ORN) Construction Awards Bolster Outlook, 09/19/2019
  Attack on Saudi Refinery: What Does it Mean for You, the Investor?, 09/19/2019
  Investing in Cannabis: Should You Go Green? , 09/19/2019
  Mortgage Rates Jump, 09/19/2019
  Voice of Blockchain to Offer Insights for all Members of the Blockchain Ecosystem, 09/19/2019
  Offshore Wind Power Blows into the Energy Market, 09/18/2019
  Directed Energy Weapons: Star Wars Redux?, 09/18/2019
  Scotiabank supports young Canadians with a $500,000 donation to the Terry Fox PROFYLE program, 09/18/2019
  How Will the Authorization of AB5 Impact Gig Economies?, 09/17/2019
  Will the Market Surpass All-Time Highs? , 09/17/2019
  Industry Report - Minerals - Insights from the Precious Metals Summit, 09/16/2019
  Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit, 09/16/2019
  ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit, 09/16/2019
  NNW News - OnDeck Survey: Economy is Top Concern for Small Businesses Ahead of 2020 Election, 09/13/2019
  Will the Oil Slowdown Provoke a Renewable Energy Takeover?, 09/13/2019
  NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Developing Revolutionary Gene Therapies to Fight Cancer, 09/13/2019
  Chek-in with Mike Kupinski and the CFO of E.W. Scripps, Lisa Knutson., 09/13/2019
  Research - Great Lakes Dredge & Dock (GLDD), 09/12/2019
  Taking the FDA shortcut, 09/12/2019
  Industry Report - Biotechnology - Key Catalysts for Oncology Companies, 09/12/2019
  Industry Report - Biotechnology - Success of Cancer Vaccines Approaching?, 09/12/2019
  Are Nanocap Stocks a Beneficial Addition to Your Portfolio?, 09/11/2019
  Hurricanes Do More Damage than What’s on the Surface , 09/11/2019
  Independent Researchers Find Genprex's TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer, 09/11/2019
  Research - Eagle Bulk Shipping (EGLE) - Signaling a Recovery, 09/10/2019
  How Can Innovations in Transportation and Logistics Provide Value to Investors?, 09/10/2019
  Cyclical Economic Shifts: Industrial Companies Could Feel the Effects, 09/10/2019
  Will the Longest Economic Expansion in History Continue? , 09/09/2019
  Can Investing in Natural Resources Provide Future Value?, 09/06/2019
  Will Renewable Energy be the Downfall of Fossil Fuels? , 09/06/2019
  Are the Trade Troubles Coming to an End?, 09/05/2019
  Prescription Drug Pricing: How Would Limited Government Intervention Change the Landscape? , 09/05/2019
  Dyadic to Present at Janney Healthcare Conference, 09/04/2019
  Everything from A-to-Z: There are Consumer Cyclical Stocks for Everyone , 09/04/2019
  Utility Stocks May Offer Low-Risk Investment Potential, 09/04/2019
  Research - QuoteMedia (QMCI) - A Look Ahead, 09/03/2019
  Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck, 09/03/2019
  ProMIS Neurosciences to Present at HC Wainwright Investment Conference, 09/03/2019
  Treasure hunt? Let’s Talk Silver, 09/03/2019
  Research - Aurania Resources (ARU:CA) - Updating Estimates, 08/30/2019
  Will the Slowing in Quarter 3 Affect Microcap Stocks? , 08/30/2019
  Worth the Risk? An Overview of Investing in Small & Microcap Stocks. , 08/30/2019
  How can Blockchain Help Accelerate the Agriculture Industry?, 08/30/2019
  Are Shipping Stocks Shipwrecked by the U.S. and China Disputes?, 08/29/2019
  How Will Rising Trade Tensions Impact the Aerospace Industry? , 08/29/2019
  IPO Podcast - Rob Lowe, 08/29/2019
  Research - One Stop Systems (OSS) - ATM Completed, 08/28/2019
  Research - E.W. Scripps (SSP) - Differentiated From Its Peers, 08/28/2019
  Research - Trovagene (TROV) - Progressing Prostate Cancer Data in Small Number of Patients, 08/27/2019
  Pharma Mergers and Acquisitions: Who’s Really Winning Here?, 08/27/2019
  Will the Uncertain Economy Boost Mining Stocks? , 08/27/2019
  NNW News - Entrepreneurs Tips To Take Gig Work To The Next Level, 08/27/2019
  NNW News - Genprex Inc. (GNPX) Making Headway in Clinical Program Expansion, Company Growth, 08/27/2019
  Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC), 08/26/2019
  What If Yields Turn Negative?, 08/26/2019
  Research - Aurania Resources (ARU.V) - A Growing Number of Targets, 08/23/2019
  Research - 1-800-Flowers.com (FLWS) - Why this quarter stands out., 08/23/2019
  Will Iran Continue to Grow Their Nuclear Program? , 08/22/2019
  Aurania Refines Its Newly Discovered Apai Gold-Silver Target in Southeastern Ecuador, 08/22/2019
  Reserach - Great Lakes Dredge & Dock (GLDD) - Backlog Rebound Expected, 08/21/2019
  The inverted yield curve: what does this really indicate? , 08/21/2019
  Can Germany Survive the Trade War?, 08/21/2019
  Research - Tribune Publishing (TPCO) - Content to Drive Value, 08/20/2019
  Microsoft Acquires PromoteIQ in an attempt to compete with Amazon, 08/20/2019
  Research - Euroseas (ESEA) -Quarterly Results Stabilizing, 08/19/2019
  Can Blockchain Revolutionize the Banking Industry?, 08/19/2019
  Growing Industry: What Should We Look For?, 08/19/2019
  Research - EuroDry (EDRY) - Improving Environment, 08/16/2019
  Research - Sierra Metals (SMTS) - Positioned for Improvement, 08/16/2019
  Research - Onconova Therapeutics (ONTX) - Inflection Points Ahead, 08/15/2019
  Too Busy to Shop? The Rise of Meal Kit Delivery Services, 08/15/2019
  Will owning an Electric Vehicle finally be convenient? , 08/15/2019
  Can consumers positively impact the current economic outlook?, 08/15/2019
  Research - Dyadic International (DYAI) - Data and Additional Partnerships to Expand Further Value, 08/14/2019
  Research - electroCore (ECOR) - Soothing Investors' Migraine a Bit?, 08/14/2019
  Research - Pangaea Logistics (PANL) - Lower 2Q2019 Shipping Days, But Rebound Ahead, 08/14/2019
  Research - ProMIS Neurosciences (PMN:CA) - Strengthening Drug Portfolio by Adding Novel Alzheimer's Antibodies, 08/14/2019
  Research - QuoteMedia, Inc. (QMCI) - Second Quarter Results Indicate Favorable Momentum, 08/14/2019
  Research - Harte Hanks (HHS) - Substantial Progress Made, 08/13/2019
  Research - Pyxis (PXS) - On Track for Rebound, 08/13/2019
  Research - E.W. Scripps (SSP) - A Surprising Reaction , 08/13/2019
  Research - Salem Media (SALM) - Hitting Fast Forward, 08/13/2019
  Can Hong Kong Retain Its Autonomy?, 08/13/2019
  FEATURE: Research | NobleCon | Podcast, 08/12/2019
  Research - Trovagene (TROV) - Inflection Points Later this Year, 08/12/2019
  Research - Endeavor Silver (EXK) - Setting the Stage for Growth, 08/12/2019
  China currency devaluation: Who is this helping?, 08/12/2019
  Research - Genco Shipping (GNK) - A Tough Quarter But Rebound Ahead, 08/09/2019
  Research - Avino Silver & Gold (ASM) - Entering the Second Half with Strong Liquidity and Leverage to Higher Commodity Price, 08/09/2019
  Research - Coeur Mining (CDE) - Momentum Building in the Second Half?, 08/09/2019
  Research - One Stop Systems (OSS) - A Solid 2Q Rebound Sets Up the Second Half of 2019, 08/09/2019
  Research - Cumulus Media (CMLS) - Favorable Cash Flow Picture Provides Confidence In Debt Reduction Target, 08/09/2019
  Research - Harte-Hanks (HHS) - With Progress Comes Increased Confidence In Its Turnaround, 08/09/2019
  Research - The McClatchy Company (MNI) - Significant Progress Toward Maintaining Cash Flow, 08/09/2019
  Research - ACCO Brands (ACCO) - New $100 Million Share Repurchase Authorization Continues Capital Return Theme, 08/08/2019
  Research - IEC Electronics (IEC) - Will they really be able to convert this backlog efficiently?, 08/08/2019
  Research - Orion Group Holdings (ORN) - A Construction Award Bolsters Robust Outlook, 08/08/2019
  Research - Kelly Services (KELYA) - Will the Second Half of 2019 Be Better than the First Half?, 08/08/2019
  Research - TherapeuticsMD (TXMD) - Promising Quarter Signaling to a Positive 2H 2019, 08/08/2019
  Research - Tribune Publishing (TPCO) - Another Beat And Raise; Will Investors Take Notice?, 08/08/2019
  Markets see a slight calm: how long will this last?, 08/08/2019
  Research - Gray Television (GTN) - Advertising Appears Resilient, 08/08/2019
  IPO Podcast - Patrick Drake, 08/08/2019
  Research - DLH Corporation (DLHC) - 3Q Post Call Analysis, 08/07/2019
  Research - Seanergy Maritime (SHIP) - Solid Quarter and Strong Start to 2H2019, 08/07/2019
  Industry Report - Biotechnology Overview, 08/07/2019
  Research - Vectrus (VEC) - Today's Investments Will Pay Off Tomorrow, 08/07/2019
  Research - Entravision Communications (EVC) - Will It Make Headway Fixing Digital?, 08/07/2019
  Research - Townsquare Media (TSQ) - Hitting a Nice Stride, 08/07/2019
  Bull or bear dollar in the near future?, 08/07/2019
  Research - Gray Television (GTN) - A Solid Quarter, 08/07/2019
  Research - ACCO Brands (ACCO) - What Will New Acquisition Mean?, 08/06/2019
  Research - DLH Holdings Corp (DLHC) - What Do 3Q19 Results Tell Us About the Combined Company?, 08/06/2019
  Research - Information Services (III) - Will Back Half of Year Be Better Than First Half?, 08/06/2019
  Research - Energy Fuels (UUUU) - Looking Ahead to Working Group Recommendations Expected in October, 08/06/2019
  Research - 1-800-Flowers.com (FLWS) - The Latest Acquisition Is The Berries, 08/06/2019
  Research - Gannett Company (GCI) - Did Gannett Get The Most It Could?, 08/06/2019
  Research - Genie Energy (GNE) - Earnings Miss Causes Decline in Stock, 08/06/2019
  Research - Ducommun (DCO) - Can Momentum in Commercial Aerospace Outlast 737 MAX Headwinds?, 08/06/2019
  Is Solar Energy the Way of the Future?, 08/05/2019
  What’s the deal with CBD?, 08/05/2019
  How far will plant-based foods go?, 08/02/2019
  What Are the Dangers of the Capital One Data Breach? , 08/02/2019
  Research - Aurania Resources (ARU.V) - Drilling Activity Expected to Accelerate in the Second Half, 08/01/2019
  Research - Prize Mining Corporation (PRZ.V) - Taking Steps to Better Position the Company in the Eyes of Investors, 08/01/2019
  Research - ACCO Brands (ACCO) - A Deeper Dive Into Record 2Q19 Results, 08/01/2019
  Research - Albany International Corp. (AIN) - Woah... Why were aerospace margins so strong this quarter?, 08/01/2019
  Research - Great Lakes Dredge & Dock (GLDD) - Fourth Strong Quarter In A Row. Backlog Rebound Ahead., 08/01/2019
  Research - Orion Group Holdings (ORN) - Rebound Appears Underway Sooner Than Expected, 08/01/2019
  Research - Kratos Defense & Security (KTOS) - Will the Outperformance Continue?, 08/01/2019
  Research - ACCO Brands (ACCO) - Record 2Q Results; What's In-store for the Rest of the Year?, 07/31/2019
  CAR-T Cancer Treatment: Part 3, When Breakthroughs Converge, 07/31/2019
  U.S. second quarter labor costs increases by the smallest amount in 1 ½ years, 07/31/2019
  IPO Podcast - Kathy Ireland, 07/31/2019
  Research - Eagle Bulk Shipping (EGLE) - A Tough Quarter But Set Up for 2H2018 Rebound, 07/30/2019
  Moderate Increase in U.S. Prices and Consumer Spending, 07/30/2019
  Tensions Rise on First Federal Reserve Rate Cut in a Decade, 07/30/2019
  Research - Orion Group Holdings (ORN) - Transition Quarter to Strong Second Half Rebound, 07/29/2019
  Research - Eurodry (EDRY) - Positive Impact from Preferred Changes and Recent Dry Bulk Market Rebound., 07/29/2019
  Research - Great Panther Mining Limited (GPL) - Turning the Corner, 07/29/2019
  Is The IRS Cracking Down On Cryptocurrency? , 07/29/2019
  Research - Kelly Services (KELYA) - Initiating Coverage; A Leading Staffing Company Poised for Additional Growth, 07/29/2019
  Research - Eagle Bulk Shipping (EGLE) - Convert Debt Funds Another Acquisition, Pressures Stock Price, 07/26/2019
  Research - Onconova Therapeutics - Initiation of Coverage, 07/25/2019
  eSports- The Next Big Thing?, 07/25/2019
  Can Micro-Mobility Solve Last-mile Transportation Issues?, 07/24/2019
  Regulatory Overstep? How will MiFID II impact financial markets?, 07/24/2019
  IPO Podcast - Christie Hefner, 07/24/2019
  IPO Podcast Series: Rob Lowe, 07/24/2019
  IPO Podcast Series-1, 07/24/2019
  IPO Podcast Series, 07/24/2019
  Research - ProMIS Neurosciences (PMN:CA) - Amid Skepticism, Light Will Emerge in Alzheimer's Area, 07/23/2019
  Research - Scorpio Bulkers (SALT) - Worst Has Passed and Rebound Underway, 07/23/2019
  Is the transportation sector signaling the next recession?, 07/23/2019
  Research - Seanergy Maritime (SHIP) - Cape Market Moving Sharply Higher, SHIP Should Move Up Too, 07/22/2019
  Cryptocurrency Controversy? Facebook Reveals Libra. , 07/22/2019
  Research - Avino Silver & Gold (ASM) - What is the Expected Impact of Phasing Out San Gonzalo?, 07/19/2019
  IPO Podcast Series: King Bach, 07/19/2019
  Research - Orion Group Holdings (ORN) - Another Project Award Boosts Record Backlog and Reinforces Positive Outlook, 07/18/2019
  Industry Report - Media - Is It Too Early To Bet On Political Advertising?, 07/18/2019
  Deepfakes: Has Artificial Intelligence Gone Too Far?, 07/18/2019
  Media Quarterly Review Q2 2019, 07/18/2019
  Research - Sierra Metals (SMTS) - Will the Momentum Continue?, 07/17/2019
  What’s Up Next for Blockchain?, 07/16/2019
  Metals And Mining Quarterly Review Q2 2019, 07/16/2019
  Energy Quarterly Review Q2 2019, 07/16/2019
  Research - Aurania Resources (ARU.V) - Employing Big Data in the Rainforests of Ecuador, 07/15/2019
  Research - Coeur Mining (CDE) - Will Recent Strength in Gold Prices Benefit Second Half Performance?, 07/15/2019
  Research - Energy Fuels (UUUU) - Section 232 Petition Prompts Working Group for More Study, 07/15/2019
  The Controversial Question: Would You Answer It?, 07/15/2019
  Can These Tech Unicorn Companies Prove Their Worth?, 07/12/2019
  Research - Endeavour Silver (EXK) - A Work In Progress, 07/11/2019
  Research - Great Panther Mining Limited (GPL) - When Will the Valuation Reflect an Improving Growth Outlook?, 07/11/2019
  Research - QuoteMedia Inc. - Initiation Report, 07/11/2019
  News - Are Driverless Vehicles Being Over-Hyped?, 07/10/2019
  Research - DLH Holdings (DLHC) - An Early Look at the Combined DLH and Social & Scientific Systems, 07/10/2019
  Research - Trovagene (TROV) - What does Colorectal Cancer Trial Add?, 07/10/2019
  News - Mission (Im)possible: (Un)druggable RAS?, 07/09/2019
  Research - Vectrus (VEC) - What does Advantor Systems add to Vectrus?, 07/09/2019
  Research - One Stop Systems (OSS) - What Impact Will the $60 Million OEM Agreement Have?, 07/09/2019
  Research - Dyadic (DYAI) - VTT to Continue Validation of C1 Platform in Bioproduction., 07/08/2019
  Fed Rate Cut: Who Does it Affect?, 07/08/2019
  Exploring a New Frontier: 5G Networking, 07/05/2019
  IPO Podcast Series: Kathy Ireland, 07/04/2019
  Research - Entravision Communications (EVC) - Sheds Light on the Matter, 07/03/2019
  Industry Report - Minerals - Are Mining Stocks Poised for a Better Second Half?, 07/03/2019
  Research - Vectrus (VEC) - Named to Another Contract; Massaging Estimate, 07/02/2019
  Industry Report - Energy - The storage numbers tell it all, 07/02/2019
  Big Tech Headed For A Big Breakup? FAANG, 07/02/2019
  Research - Seanergy Maritime (SHIP) - Class C Warrants Expanding Share Count, 07/01/2019
  Peace At Last? U.S.-China Announce Trade Truce, 07/01/2019
  Research - Prize Mining (PRZ) - Charting a Course for Kena Gold Property, 06/28/2019
  IPO Podcast Series: Christie Hefner, 06/27/2019
  News - Wind Energy: Is it efficient enough?, 06/25/2019
  Research - Great Lakes Dredge (GLDD) - More Awards Announced; 2H3019 Backlog Expected, 06/25/2019
  Research - Euroseas (ESEA) - Acquisition and Financing Activity Are Positives, 06/24/2019
  News - CFA, CFP, CPA, CAIA, ChFC, CIPM, OMG when will it end?, 06/21/2019
  FEATURE: NobleCon 16 | Tanker Attack | Research | Podcast, 06/20/2019
  Research - Great Lakes Dredge (GLDD) - Awards Boost Confidence, 06/20/2019
  News - A Chimera for the Treatment of Cancer (Part 2), 06/20/2019
  Research - Endeavour Silver (EXK) - Signs of an Improving Outlook?, 06/19/2019
  Research - TherapeuticsMD (TXMD) - What Investors are Missing, 06/19/2019
  Research - Upgrading the Shares - High Risk but High Upside Potential, 06/17/2019
  News - What will the Persian Gulf attack mean for oil prices?, 06/17/2019
  Research - Aurania Resources - Lessons from Crunchy Hill, 06/14/2019
  Noble Capital Markets’ sixteenth annual investor conference, 06/14/2019
  Research - Cumulus Media (CMLS) - Debt Recovery Should Help Stock, 06/13/2019
  Research - DLH Holdings Corp. (DLHC) - Potential Transformative Factors, 06/13/2019
  Research - KeyW Holding (KEYW) - Jacobs Tender Offer Completed, 06/13/2019
  Research - Townsquare Media (TSQ) - Why is the stock below its peers?, 06/11/2019
  Research - electroCore (ECOR) - ECOR Braves Choppy Waters, 06/11/2019
  Research - Comtech (CMTL) - Can the Current Upswing be Maintained?, 06/07/2019
  News - A Chimera Becomes a Novel Cancer Treatment (Part 1), 06/06/2019
  Research - Comtech (CMTL) - Q3 Delivers Record Backlog, 06/06/2019
  Research - electroCore (ECOR) - Departing Founder and Chief Science and Strategy Officer, 06/05/2019
  Research - Kratos (KTOS) - Price Appreciation Pushes to Market Perform, 06/05/2019
  News - Tariffs Make a Run for the Border, 06/04/2019
  Research - Aurania Resources (ARU.V) - Copper Exploration Yields Encouraging Results, 05/31/2019
  Research - electroCore (ECOR) - Plans to Remove Headwinds, 05/31/2019
  News - The Great Debate: Active or Passive Management?, 05/30/2019
  Research - Euroseas (ESEA) - Price Target Revision, 05/30/2019
  News - Will electric cars stall the demand for oil?, 05/28/2019
  Research - EuroDry (EDRY) - Increasing EBITDA Estimate, 05/28/2019
  Research - Pyxis Tankers (PXS) - Still Looking for a Recovery, 05/24/2019
  Research - Trovagene (TROV) - Agreement with Nektar Therapeutics, 05/24/2019
  Research - McClatchy (MNI) - Raising Our Rating, 05/23/2019
  News - Videogames: The Next Professional Sport, 05/22/2019
  Research - Pangea Logistics (PANL) - New Dividend, 05/21/2019
  Research - Great Panther Silver (GPL) - Reports first quarter loss, 05/17/2019
  Research - Pangaea Logistics (PANL) - Another Solid Quarter; Consistent Business Model, 05/17/2019
  Research - One Stop Systems (OSS) - Files $100 Million Shelf Registration, 05/17/2019
  Research - Entravision (EVC) - Investor Call Highlights, 05/17/2019
  Research - electroCore (ECOR) - Stock price doesn't reflect the value of gammaCore, 05/17/2019
  Research - electroCore (ECOR) - First quarter 2019 results are below expectations, 05/16/2019
  Research - Entravision (EVC) - First quarter 2019 update, 05/16/2019
  Research - Sierra Metals (SMTS) - Reports first quarter loss, 05/15/2019
  Research - ProMIS Neurosciences (PMN:CA) - First quarter 2019 progression, 05/15/2019
  Research - Genco Shipping (GNK) - Adjusting estimates; weak market environment, 05/14/2019
  Research - E.W. Scripps (SSP) - Lowering price target, 05/14/2019
  Research - Avino Silver & Gold (ASM) - First quarter results, updating estimates, 05/13/2019
  News - Will Green Dreams Turn Into Coal’s Nightmare?, 05/13/2019
  Research - Information Services (III) - First quarter 2019 results, 05/13/2019
  Research - Ducommun (DCO) - Rating changed to Market Perform, 05/13/2019
  Research - Energy Fuels (UUUU) - Weaker than expected first quarter results, 05/13/2019
  Research - Seanergy (SHIP) - Rating updated to Market Perform, 05/13/2019
  Research - Salem Media (SALM) - First quarter comes in as expected, 05/13/2019
  Research - Trovagene (TROV) - First quarter 2019 update, 05/10/2019
  Research - Tegna (TGNA) - Raising price target, 05/10/2019
  Research - Dyadic (DYAI) - More deals appear likely., 05/10/2019
  Research - Cumulus Media (CMLS) - First quarter over delivers, 05/10/2019
  Research - One Stop Systems (OSS) - First quarter revenue miss, 05/10/2019
  Research - Gray Television (GTN) - Exceeds Q1 Expectations, 05/09/2019
  Research - Eagle Bulk Shipping (EGLE) - Another solid quarter of outperformance, 05/09/2019
  Research - DLH (DLHC) - Tweaking estimates slightly, 05/09/2019
  Research - IEC Electronics (IEC) - Delivering Consistent Organic Growth, 05/09/2019
  Research - Harte-Hanks (HHS) - First quarter 2019 update, 05/09/2019
  Research - Tribune Publishing (TPCO) - First quarter better than expected, 05/09/2019
  Research - Kratos Defense (KTOS) - 1Q19 Above Expectations, 05/09/2019
  Research - Townsquare Media (TSQ) - Digital business flourishes, 05/08/2019
  Research - Vectrus (VEC) - First quarter 2019 update, 05/08/2019
  Research - electroCore (ECOR) - Initiation of Coverage, 05/08/2019
  News - Cell Cycle Regulators as Cancer Therapeutics, 05/08/2019
  Research - Dyadic (DYAI) - Another licensing agreement, 05/08/2019
  Research - Entravision (EVC) - Update on full year 2018 results, 05/08/2019
  Research - KeyW (KEYW) - First quarter 2019 results, 05/08/2019
  Research - DLH Holdings (DLHC) - Second quarter 2019 Review, 05/08/2019
  Research - TherapeuticsMD (TXMD) - First quarter 2019 earnings update, 05/07/2019
  Research - Ducommun (DCO) - First quarter 2019 review, 05/07/2019
  Research - Endeavour Silver (EXK) - Rating lowered to Market Perform, 05/07/2019
  Research - Genie Energy (GNE) - Increasing estimates; strong results, 05/07/2019
  Research - Coeur Mining (CDE) - Review of first quarter 2019, 05/03/2019
  Research - ACCO Brands (ACCO) - Raising price target, 05/03/2019
  News - Game of Thrones: Energy Battles, 05/03/2019
  Research - Aurania Resources (ARU.V) - Drilling results analysis, 05/03/2019
  Research - Albany International (AIN) - First quarter 2019 review, 05/02/2019
  Research - Great Lakes Dredge & Dock (GLDD) - Strong third quarter, 05/01/2019
  Research - 1-800-Flowers.com (FLWS) - Fiscal 3Q19 Update, 05/01/2019
  Research - Comtech (CMTL) - Analysis of new contract and acquisition, 04/30/2019
  Research - Scorpio Bulkers (SALT) - First Quarter 2019 Review, 04/30/2019
  Research - Dyadic (DYAI) - Expanding partnership portfolio, 04/30/2019
  Research - TherapeuticsMD (TXMD) - Assumption of Coverage, 04/29/2019
  Research - Coeur Mining (CDE) - Updating estimates, 04/26/2019
  Research - Genprex (GNPX) - Initiation of Coverage, 04/26/2019
  News - Tax Cuts and Jobs Act: Are we better off?, 04/26/2019
  News - Blockchain for Business: Worth the Hype?, 04/25/2019
  Research - KeyW (KEYW) - Announces Definitive Merger Agreement, 04/23/2019
  Research - Aurania Resources (ARU:CA) - Appoints new CFO, 04/23/2019
  News - Uranium Imports: Trade War Goes Nuclear, 04/22/2019
  News - Does A 70% Top Marginal Tax Rate Make Sense?, 04/18/2019
  News - Boeing 737 MAX: Is it safe to fly? , 04/17/2019
  Research - Avino Silver & Gold (ASM) - Mine exploration provides optimism, 04/17/2019
  Research - Sierra Metals (SMTS) - Full year projection estimates, 04/17/2019
  Research - Vectrus (VEC) - Award is a big win, 04/17/2019
  IPO Podcast Series: Drug Disruption, 04/16/2019
  Research - Cumulus Media (CMLS) - , 04/16/2019
  Research - Coeur Mining (CDE) - First quarter production results, 04/15/2019
  Research - Endeavour Silver (EXK) - Waiting for a turnaround, 04/15/2019
  Research - Dyadic (DYAI) - Nasdaq Up-Listing Approved, 04/15/2019
  Research - Scorpio Bulkers (SALT) - Liquidity boost; adjusting estimates, 04/12/2019
  Research - Great Panther Silver (GPL) - Production numbers slightly lower than expected, 04/11/2019
  Research - Aurania Resources (ARU:CA) - Another promising copper target, 04/10/2019
  News - Could renewables supply 50% of all generation? How about 80%?, 04/05/2019
  Research - One Stop Systems (OSS) - Initiation of Research Coverage, 04/04/2019
  News - Stock Buybacks: Good, evil, or maybe something in between?, 04/03/2019
  Research - Prize Mining (PRZ:CA) - Behind the recent deal, 04/03/2019
  Research - Aurania Resources (ARU:CA) - Updates on copper production, 04/03/2019
  News - Macular Edema: The search for the cure continues, 04/02/2019
  Research - Trovagene (TROV) - Update on data readout, 04/02/2019
  Research - Trovagene (TROV) - Updated prostate cancer data, 04/02/2019
  Research - Sierra Metals (SMTS) - 2018 full year recap, 04/01/2019
  Research - Albany International (AIN) - Appoints new CFO, 04/01/2019
  Research - Pyxis Tankers (PXS) - 2018 financial update, 03/29/2019
  Research - Dyadic (DYAI) - 2018 full year update, 03/28/2019
  Podcast Launch: The Science of Investing in Biotechs, 03/28/2019
  A Video Introduction to Enochian Biosciences, 03/28/2019
  Official Trailer: NEW Podcast Series- Icons of Business, Leaders of Emerging Companies, 03/26/2019
  Research - Information Services (III) - Favorable risk/reward moving forward, 03/25/2019
  Research - Torchlight Energy - Strong updates on project estimates, 03/25/2019
  Research - 1-800-Flowers.com (FLWS) - Investor Day Highlights, 03/25/2019
  Research - Prize Mining (PRZ:CA) - Initiation of Research Coverage, 03/25/2019
  News - The Case for Dr. Copper: New Sources of Demand are Positive for Copper, 03/25/2019
  Research - Cumulus Media (CMLS) -- Raising Price Target, 03/22/2019
  Research - Pangaea Logistics (PANL) - Business Model/Strategy Shine, 03/22/2019
  Research - Seanergy (SHIP) - What do the results show?, 03/21/2019
  Research - E.W. Scripps - Analysis of recent acquisitions, 03/21/2019
  Research - ProMIS Neurosciences (PMN:CA) - Potential opportunity in Alzheimer's , 03/21/2019
  Research - Genie Energy (GNE) - Initiation Report, 03/20/2019
  Research - E.W. Scripps (SSP) - Acquiring stations, building portfolio, 03/20/2019
  Research - Tegna (TGNA) - Acquisition highlights, 03/20/2019
  Research - Information Services (III) - 2019 growth possibilities, 03/18/2019
  Research - Tribune Publishing (TPCO) - Behind the numbers , 03/18/2019
  Research - Harte-Hanks (HHS) - The focus towards growth, 03/15/2019
  Research - Information Services (III) - Q4 review; the full story, 03/15/2019
  News - Artificial Intelligence: Can an algorithm do what you do?, 03/14/2019
  Research - Townsquare Media (TSQ) - Quarter over delivers, 03/14/2019
  Research - Tribune Publishing (TPCO) - Looking forward into 2019, 03/14/2019
  Research - KeyW (KEYW) - What will drive 2019 performance?, 03/13/2019
  Research - Townsquare Media (TSQ) - Revenues surprise, 03/13/2019
  Research - Salem Media (SALM) - Looking past the first quarter 2019, 03/13/2019
  Research - Energy Fuels (UUUU) - Updating estimates, 03/13/2019
  News - CRISPR-Cas9: Editing away sickness, 03/13/2019
  Research - Gannett (GCI) - Favorable risk/reward, 03/12/2019
  Research - Comtech Telecommunications (CMTL) - Deeper dive in 2Q19 results, 03/12/2019
  Research - Euroseas (ESEA) - Lowering Price Target, 03/12/2019
  Research - Aurania Resources (ARU:CA) - New drilling has commenced, Funding secured, 03/11/2019
  Research - Great Lakes Dredge (GLDD) - Investor Meeting Highlights, 03/11/2019
  News - Green New Deal: Environment Savior or Economy Destroyer?, 03/08/2019
  Research - McClatchy (MNI) - Outlook for 2019, 03/08/2019
  Research - Trovagene (TROV) - 2018 full year update, 03/08/2019
  News - Do We Need to Prepare for War in Space?, 03/07/2019
  Research - Eagle Shipping (EGLE) - Long-term outlook positive, 03/07/2019
  Research - Comtech (CMTL) - Exceeds 2Q quarterly expectations, 03/07/2019
  Research - Kratos Defense (KTOS) - Drone prospect takes flight, 03/07/2019
  News - DNA Data Storage: The Future of Informatics, 03/06/2019
  Research - Genco Shipping (GNK) - 4Q18 Results Surprise , 03/06/2019
  Research - E.W. Scripps (SSP) - Raising Price Target, 03/05/2019
  NobleConXV Panel - Marketing Early-Stage Natural Resource Companies to Investors, 03/05/2019
  Research - Tegna (TGNA) - Looking towards subscriber growth in 2019, 03/04/2019
  Research - Great Panther Silver (GPL) - Expectations in line, 03/04/2019
  Research - Kratos Defense (KTOS) - Acquisition announced, 03/01/2019
  Research - Gray Television (GTN) - 2018 full year results, 03/01/2019
  Research - Avino Silver (ASM) - Increasing 2019 estimates, 03/01/2019
  Research - Ducommun (DCO) - 2018, the inflection year, 03/01/2019
  News - Merger Mania Hits the Mining Space, 03/01/2019
  News - Electric Cars: Time to plug in?, 02/28/2019
  News - Could the US Have More Oil than the Saudis?!, 02/27/2019
  News - Cannabiz: Growing Like a Weed, 02/26/2019
  Research - Cumulus Media (CMLS) - Earnings preview, 02/26/2019
  News - Legalizing Sports Gambling: Place Your Bets, 02/25/2019
  News - Alzheimer’s, Cannibals, and the Scientist Who Saw the Connection, 02/22/2019
  Research - Cumulus Media (CMLS) - Raising price target, 02/14/2019
  News - High-yield bonds: Trash or Treasure?, 02/13/2019
  News - Trump vs Obama: Who did the first two years better?, 02/12/2019
  A MUST WATCH - panel of key opinion leaders - a cure for diabetes, 02/11/2019
  The business of cannabis - WATCH an industry panel break it all down, 02/11/2019
  WORTH READING - Electric Cars, OPEC Today, FED Impact, 02/11/2019
  Channelchek in Forbes - referenced as a gatekeeper for emerging growth companies, 02/11/2019
  NobleConXV Keynote Address, 02/05/2019
  NobleConXV Webcasts, 02/04/2019
  News - The Great Wall of America, 01/24/2019
  News - Is OPEC still king of oil?, 01/24/2019
  News - End of an Era: Sears Struggles to Survive, 01/23/2019
  News - Buybacks: Who benefits?, 01/21/2019
  News - Robinhood: Could it steal customers from the banks?, 12/31/2018
  News - Holiday Havoc: Why December turned into a tough time for investors, 12/27/2018
  News - The Fed raised its rates, now what?, 12/19/2018
  News - Polo-like kinases inhibitors are novel drug targets of cancer therapeutics, 12/14/2018
  News - Can manufacturing keep up with demand for biologic drugs?, 12/04/2018
  News - HIV - Could there be a cure?, 12/01/2018
  News - Gold - Trending Up?, 11/27/2018
  Welcome to Channelchek video, 11/20/2018
  News - Cancer - Harnessing the power of immune system, 11/15/2018
  News - Cancer - Gene therapy, what the future holds, 11/15/2018
  News - Alzheimer’s - The race to a better treatment, 11/15/2018
  News - Trump – Is he right to withdraw from INF?, 11/15/2018
  News - Cancer – Is combination therapy the answer?, 11/15/2018
My Favorites
Movers